A 10% reduction in calorie intake during the first month of treatment shows promise for augmenting chemotherapy treatment in children and adolescents with ALL.
A comprehensive review provides clinical pearls and approaches to consider regarding chemoradiotherapy for patients with stage III non-small cell lung cancer.
The immune cells in the microenvironment can reign in myeloma cells but become suppressed and dysregulated during disease progression.
The higher contrast of this tool is better than film-screen mammography at detecting calcifications that are key to diagnosing DCIS.
In an international, multicenter collaboration, experts modified the RECIST criteria for use as objective endpoints in clinical trials of retinoblastoma therapies.
Throughout the COVID-19 pandemic, clinicians who care for patients with lung cancer have made multiple treatment approach changes for this vulnerable population.
A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma.
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
The COVID-19 pandemic sheds new light on existing access challenges in preventive health care.
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
New NCCN guidelines for Wilms tumor contain up-to-date information on screening, diagnosis, risk stratification, and treatment for this rare childhood renal cancer.
Diabetes and metabolic syndrome represent two of the most common long-term complications in survivors of childhood cancer.
Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.
To prove clinical benefit, the FDA requires manufacturers to conduct confirmatory trials, also known as a phase 4 studies.